Fig. 1.
Effect of marrow cell dose (nucleated cells × 108/kg of recipient body weight) on (A) prevalence of neutrophil count above 0.5 × 109/L, (B) cumulative incidence of achieving a self-sustained platelet count greater than 50 × 109/L, (C) cumulative incidence of grade III-IV acute GVHD, (D) cumulative incidence of nonleukemic death after transplant in remission, (E) estimated RR of nonleukemic death in transplants in remission showing a linear decrease in the RR by increasing marrow cell dose (the dashed lines limit 95% CI), (F ) leukemia-free survival after transplant in remission.
